8 June 2026
Latham Advises Mineralys Therapeutics in Unique Three-Pronged Transaction — Royalty Repurchase, Debt Financing, and Equity Offering — Totaling Up to US$950 Million
Advising firms
Deal team
22 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Cheston Larson Lead | Latham & Watkins LLP | Partner | equity offering | Not stated |
| Matt Bush Lead | Latham & Watkins LLP | Partner | equity offering | Not stated |
| Haim Zaltzman Lead | Latham & Watkins LLP | Partner | debt financing | Not stated |
| Elizabeth Oh Lead | Latham & Watkins LLP | Partner | debt financing | Not stated |
| Kate Hillier Lead | Latham & Watkins LLP | Partner | royalty buyout | Not stated |
| Anthony Gostanian | Latham & Watkins LLP | Counsel | equity offering | Not stated |
| Rachel Staub | Latham & Watkins LLP | Associate | equity offering | Not stated |
| Omeed Valipour | Latham & Watkins LLP | Associate | equity offering | Not stated |
| Benjamin Gelfand | Latham & Watkins LLP | Counsel | debt financing | Not stated |
| Ian Drazen | Latham & Watkins LLP | Associate | debt financing | Not stated |
| Arun Mohan | Latham & Watkins LLP | Associate | royalty buyout | Not stated |
| Robert Yeh | Latham & Watkins LLP | Counsel | intellectual property | Not stated |
| Patrick Chew | Latham & Watkins LLP | Associate | intellectual property | Not stated |
| Elizabeth Richards | Latham & Watkins LLP | Partner | FDA matters | Not stated |
| Chad Jennings | Latham & Watkins LLP | Counsel | FDA matters | Not stated |
| Nicole Liffrig Molife | Latham & Watkins LLP | Counsel | healthcare matters | Not stated |
| Heather Deixler | Latham & Watkins LLP | Partner | data privacy and HIPAA matters | Not stated |
| Chad Leiper | Latham & Watkins LLP | Associate | data privacy and HIPAA matters | Not stated |
| Aryeh Zuber | Latham & Watkins LLP | Counsel | ERISA matters | Not stated |
| Reza Mojtabaee-Zamani | Latham & Watkins LLP | Partner | convertible securities matters | Not stated |
| Claire Solimine | Latham & Watkins LLP | Associate | convertible securities matters | Not stated |
| Eric Cho | Latham & Watkins LLP | Partner | tax matters | Not stated |
19 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 950m (US$950 Million)
- What the figure measures
- Total transaction value
- Client
- Mineralys Therapeutics, Inc.Issuer
- Counterparties
- Tanabe Pharma Corporation (Sell-side)
Pharmakon Advisors, LP (Lenders)